NCT02586987 is a Phase 1 clinical trial of Selumetinib in Lung Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT02586987?

NCT02586987 is sponsored by AstraZeneca.

What drugs are being tested in NCT02586987?

Interventions in NCT02586987: Selumetinib, MEDI4736, Tremelimumab.

What condition does NCT02586987 study?

NCT02586987 studies Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer.

Is NCT02586987 still recruiting?

NCT02586987 is currently completed. Last updated 18 November 2019.

Last reviewed 2019-11-18 · How we verify

NCT02586987

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Completed Phase 1 Last updated 18 November 2019

What this trial tests

Phase 1 trial testing Selumetinib in Lung Cancer in 58 participants. Completed in 20 September 2019.

Timeline

28 December 2015

Primary endpoint
25 July 2018

20 September 2019

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	28 December 2015
Primary completion	25 July 2018
Estimated completion	20 September 2019
Sites	6 locations across United States

Drugs / interventions tested

Selumetinib — full drug profile →
MEDI4736 — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Melanoma — all drugs for Melanoma →
Head and Neck Carcinoma — all drugs for Head and Neck Carcinoma →
Gastroesophageal Cancer — all drugs for Gastroesophageal Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 99, any sex, with Lung Cancer or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive review of targeted therapy for colorectal cancer.
Xie YH, Chen YX, Fang JY. · · 2020 · cited 1162× · PMID 32296018 · DOI 10.1038/s41392-020-0116-z
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Current Advances in the Treatment of BRAF-Mutant Melanoma.
Patel H, Yacoub N, Mishra R, White A, et al · · 2020 · cited 133× · PMID 32092958 · DOI 10.3390/cancers12020482
Durvalumab: First Global Approval.
Syed YY. · · 2017 · cited 130× · PMID 28643244 · DOI 10.1007/s40265-017-0782-5
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer.
Saka D, Gökalp M, Piyade B, Cevik NC, et al · · 2020 · cited 106× · PMID 32823814 · DOI 10.3390/cancers12082274
Immunotherapy for Colorectal Cancer.
Boland PM, Ma WW. · · 2017 · cited 105× · PMID 28492495 · DOI 10.3390/cancers9050050
Immunobiology of cholangiocarcinoma.
Loeuillard E, Conboy CB, Gores GJ, Ilyas SI. · · 2019 · cited 88× · PMID 32039381 · DOI 10.1016/j.jhepr.2019.06.003
Biliary tract cancers: current knowledge, clinical candidates and future challenges.
Tariq NU, McNamara MG, Valle JW. · · 2019 · cited 79× · PMID 31015767 · DOI 10.2147/cmar.s157092

Verify or expand the search:

Other trials of Selumetinib

Trials testing the same drug.

NCT06735820 — Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST · Phase 1, PHASE2 · not yet recruiting
NCT06188741 — Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 · Phase 2 · recruiting
NCT06763315 — Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children · Phase 2 · not yet recruiting
NCT06621082 — The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule · Phase 2 · not yet recruiting
NCT06620354 — Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule · Phase 2 · not yet recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02586987 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 18 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02586987.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing